| Ticker: CNCT | 3400 West Bayshore Road | |
| Exchange: NASDAQ-National Market | Palo Alto, California 94303 | |
| Industry: Manufacturing | (415) 843-2800 |
| Type of Shares: | Common Shares | Filing Date: | 12/11/95 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 1/31/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $11.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.77 | |
| Offering Amount: | $30,000,000 | Selling: | $0.46 | |
| Expenses: | $900,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,373,648 |
| Manager | Tier | Phone |
| Smith Barney Inc. | Lead Manager | (718) 921-8473 |
| Dillon, Read & Co. Inc. | Co-manager | (212) 906-7000 |
| Punk, Ziegel & Knoell | Co-manager | (212) 308-9494 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $0.00 | Assets: | $11.80 | ||
| Net Income: | -$10.37 | Liabilities: | $11.73 | ||
| EPS: | -$1.79 | Equity: | $0.06 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is focused on the development of therapeutics to address serious diseases involving the connective tissues of the body. Connective tissues are components of the body that form structural or binding elements such as skin, ligaments and lining of organs, and form the three-dimensional structure that allows cells to function normally. The indications or conditions initially addressed by the company include atopic dermatitis, keloids, scleroderma, multiple sclerosis, organ fibrosis and rheumatoid arthritis. Although individually these diseases have been the subject of various independent research programs, no concentrated effort has been aimed at developing this market segment as a whole, representing significant and currently underserved market opportunities. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund clinical development and manufacturing, preclinical research, the repayment of debt, working capital, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.